Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that
its partner Spectrum Pharmaceuticals (NASDAQ: SPPI) has submitted a New
Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)
for Captisol-enabled™ Melphalan (CE-Melphalan) HCl for injection
(propylene glycol-free) for use as a high-dose conditioning treatment
prior to hematopoietic progenitor (stem) cell transplantation in
patients with multiple myeloma.
for Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for Captisol-Enabled™ Melphalan investment picks